MedWatch

Dicerna CEO explains how a desire to expand collaborations turned into a potential acquisition

Novo Nordisk's possible billion-dollar takeover of US-based Dicerna, which was announced last week, stems from a suggestion to extend their partnership, CEO at Dicerna Douglas Fambrough tells MedWatch, and Novo Nordisk confirms.

What could end up being Novo Nordisk's biggest deal in recent times actually began as a wish to expand the collaboration with the US-based Dicerna around three months ago, says the latter company's CEO Douglas Fambrough.

Last week, Novo Nordisk unveiled the potential acquisition deal to the public, saying that the takeover's price tag would read USD 3.3bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs